Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 612-616

  Strauss, H G ^a   Henze, A ^b   Teichmann, A ^b   Karbe, I ^a   Baumgart, A ^c   Thomssen, C ^a   Koelbl, H ^d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Department of Obstetrics and Gynecology ^*  (Germany)

^c Sanofi   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Carboplatin; Clinical trial; Docetaxel; Platinum sensitive ovarian cancer; Relapsed ovarian cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TOLERABILITY; DYSPNEA; EPIPHORA; FEMALE; HUMAN; HYPOTENSION; INFECTION COMPLICATION; KIDNEY FUNCTION; LIVER FUNCTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REPEATED DRUG DOSE; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; UTERINE TUBE TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TAXOIDS;

EID: 33846913009     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.023     Document Type: Article

References (15)

1. Pfisterer J., Harter P., Canzler U., et al. AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR). The role of surgery in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15 Suppl. 3 (2005) 195-198
2. Meier W., du Bois A., Kuhn W., et al. Topotecan vs treosulfan in recurrent ovarian cancer after initial therapy with platinum and paclitaxel. A prospective randomized phase III study. Proc. ASCO (2003) #1810
3. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
4. Parmar M.K.B., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based, chemotherapy in women with relapsed ovarian cancer: the ICON 4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
5. Pfisterer J., Vergote I., Du Bois A., and Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15 Suppl 1 (2005) 36-41
6. Rose P.G., Smrekar M., Haba P., Visser C., and Beeler J. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol. Oncol. 99 (2005) 714-719
7. Rothermundt C., Hubner R., Ahmad T., et al. Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second-or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. Br. J. Cancer 94 (2006) 74-78
8. Simon R. Optimal two-stage-designs for phase II clinical trials. Control. Clin. Trials 10 (1998) 1-10
9. du Bois A., Lueck H.J., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
10. du Bois A., Quinn M., Thigpen T., et al. 2004 consensus statement on the management of ovarian cancer: final document of the 3rd International Gynecologic Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16 Suppl 8 (2005) 7-12
11. Lin Y.C., Chang H.K., Wang C.H., et al. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthra-cyclines and paclitaxel: partial cross resistance between paclitaxel and docetaxel. Anticancer Drugs 11 (2000) 617-621
12. Yonemori K., Katsumata N., Uno H., et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res. Treat. 89 (2005) 237-241
13. Viens P., Petit T., Yovine A., et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann. Oncol. 17 (2006) 429-436
14. Vasey A., Jason G.C., and Gordon A. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
15. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153